Biogen
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
With a market cap of 30.78B, Biogen(BIIB) trades at $207.68. The stock has a price-to-earnings ratio of 23.19.
On 2026-07-06, Biogen(BIIB) stock traded between a low of $207.68 and a high of $215.95. Shares are currently priced at $207.68, which is 0.0% above the low and -3.8% below the high.
Biogen(BIIB) shares are trading with a volume of 1.21M, against a daily average of 1.37M.
In the last year, Biogen(BIIB) shares hit a 52-week high of $219.72 and a 52-week low of $121.05.
In the last year, Biogen(BIIB) shares hit a 52-week high of $219.72 and a 52-week low of $121.05.
BIIB News
Biopharmaceuticals Analyst Pachaiyappan, along with Prof. Jeremy Shefner, M.D., Ph.D. (Barrow Neurological Institute), hold a webinar entitled, “A Quest to Outr...
HSBC analyst Morten Herholdt raised the firm’s price target on Biogen (BIIB) to $157 from $150 and keeps a Reduce rating on the shares. In a sector note on Heal...
In late June 2026, Biogen announced it would present new clinical, biomarker and safety data from its Alzheimer’s portfolio at AAIC 2026 in London, including Ph...
Analyst ratings
58%
of 38 ratingsMore BIIB News
Advertisement Why Biogen’s AAIC 2026 data drop matters for the stock Biogen (BIIB) is in focus as it prepares to share detailed diranersen Phase 2 results and...
Biogen (BIIB +3.04%) built itself into a biotech giant thanks to its portfolio of multiple sclerosis (MS) drugs -- but in biotech and pharma, revenue growth dep...
Biogen stock has delivered a strong 57.5% return over the past year, yet the broader valuation checks suggest the shares now look closer to fairly priced than c...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.